Medifast, Inc. (NYSE: MED) Stock Competitors & Peer Comparison

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, SCI has a market cap of 10.6B. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while SCI trades at $77.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas SCI's P/E ratio is 20.14. In terms of profitability, MED's ROE is -0.13%, compared to SCI's ROE of +0.40%. Regarding short-term risk, MED is more volatile compared to SCI. This indicates higher risk in terms of short-term price fluctuations for MED.Check SCI's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, ANDG has a market cap of 6.2B. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while ANDG trades at $54.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas ANDG's P/E ratio is 18.67. In terms of profitability, MED's ROE is -0.13%, compared to ANDG's ROE of -0.19%. Regarding short-term risk, MED is more volatile compared to ANDG. This indicates higher risk in terms of short-term price fluctuations for MED.Check ANDG's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, HRB has a market cap of 5.6B. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while HRB trades at $44.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas HRB's P/E ratio is 8.43. In terms of profitability, MED's ROE is -0.13%, compared to HRB's ROE of -2.29%. Regarding short-term risk, MED is more volatile compared to HRB. This indicates higher risk in terms of short-term price fluctuations for MED.Check HRB's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, FTDR has a market cap of 5.5B. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while FTDR trades at $78.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas FTDR's P/E ratio is 17.51. In terms of profitability, MED's ROE is -0.13%, compared to FTDR's ROE of +1.02%. Regarding short-term risk, MED is more volatile compared to FTDR. This indicates higher risk in terms of short-term price fluctuations for MED.Check FTDR's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, DSEY has a market cap of 2.7B. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while DSEY trades at $8.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas DSEY's P/E ratio is -14.47. In terms of profitability, MED's ROE is -0.13%, compared to DSEY's ROE of -0.23%. Regarding short-term risk, MED is more volatile compared to DSEY. This indicates higher risk in terms of short-term price fluctuations for MED.Check DSEY's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, MCW has a market cap of 2.3B. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while MCW trades at $7.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas MCW's P/E ratio is 21.52. In terms of profitability, MED's ROE is -0.13%, compared to MCW's ROE of +0.10%. Regarding short-term risk, MED is more volatile compared to MCW. This indicates higher risk in terms of short-term price fluctuations for MED.Check MCW's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, ROVR has a market cap of 2B. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while ROVR trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas ROVR's P/E ratio is 183.25. In terms of profitability, MED's ROE is -0.13%, compared to ROVR's ROE of -0.07%. Regarding short-term risk, MED is more volatile compared to ROVR. This indicates higher risk in terms of short-term price fluctuations for MED.Check ROVR's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, CSV has a market cap of 482.7M. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while CSV trades at $30.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas CSV's P/E ratio is 9.68. In terms of profitability, MED's ROE is -0.13%, compared to CSV's ROE of +0.17%. Regarding short-term risk, MED is less volatile compared to CSV. This indicates lower risk in terms of short-term price fluctuations for MED.Check CSV's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, EM has a market cap of 303.1M. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while EM trades at $1.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas EM's P/E ratio is -119.50. In terms of profitability, MED's ROE is -0.13%, compared to EM's ROE of -0.01%. Regarding short-term risk, MED is more volatile compared to EM. This indicates higher risk in terms of short-term price fluctuations for MED.Check EM's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, WW has a market cap of 159.1M. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while WW trades at $16.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas WW's P/E ratio is -3.31. In terms of profitability, MED's ROE is -0.13%, compared to WW's ROE of -0.34%. Regarding short-term risk, MED is less volatile compared to WW. This indicates lower risk in terms of short-term price fluctuations for MED.Check WW's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, RGS has a market cap of 66.7M. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while RGS trades at $26.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas RGS's P/E ratio is 9.86. In terms of profitability, MED's ROE is -0.13%, compared to RGS's ROE of +0.04%. Regarding short-term risk, MED is less volatile compared to RGS. This indicates lower risk in terms of short-term price fluctuations for MED.Check RGS's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, XSPA has a market cap of 54.5M. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while XSPA trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas XSPA's P/E ratio is 21.83. In terms of profitability, MED's ROE is -0.13%, compared to XSPA's ROE of +11.90%. Regarding short-term risk, MED is less volatile compared to XSPA. This indicates lower risk in terms of short-term price fluctuations for MED.Check XSPA's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, XWEL has a market cap of 7.1M. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while XWEL trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas XWEL's P/E ratio is -0.17. In terms of profitability, MED's ROE is -0.13%, compared to XWEL's ROE of +3.18%. Regarding short-term risk, MED is more volatile compared to XWEL. This indicates higher risk in terms of short-term price fluctuations for MED.Check XWEL's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, EJH has a market cap of 4.3M. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while EJH trades at $1.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas EJH's P/E ratio is -0.03. In terms of profitability, MED's ROE is -0.13%, compared to EJH's ROE of +0.01%. Regarding short-term risk, MED is less volatile compared to EJH. This indicates lower risk in terms of short-term price fluctuations for MED.Check EJH's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, MRM has a market cap of 4M. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while MRM trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas MRM's P/E ratio is 0.92. In terms of profitability, MED's ROE is -0.13%, compared to MRM's ROE of -0.68%. Regarding short-term risk, MED is less volatile compared to MRM. This indicates lower risk in terms of short-term price fluctuations for MED.Check MRM's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, FMFC has a market cap of 3.8M. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while FMFC trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas FMFC's P/E ratio is -20.90. In terms of profitability, MED's ROE is -0.13%, compared to FMFC's ROE of +0.01%. Regarding short-term risk, MED is less volatile compared to FMFC. This indicates lower risk in terms of short-term price fluctuations for MED.Check FMFC's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, IVP has a market cap of 85.8K. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while IVP trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas IVP's P/E ratio is -0.00. In terms of profitability, MED's ROE is -0.13%, compared to IVP's ROE of -3.14%. Regarding short-term risk, MED is more volatile compared to IVP. This indicates higher risk in terms of short-term price fluctuations for MED.Check IVP's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, TMX has a market cap of 0. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while TMX trades at $11.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas TMX's P/E ratio is 21.33. In terms of profitability, MED's ROE is -0.13%, compared to TMX's ROE of -0.02%. Regarding short-term risk, MED is less volatile compared to TMX. This indicates lower risk in terms of short-term price fluctuations for MED.Check TMX's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, NEBCU has a market cap of 0. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while NEBCU trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas NEBCU's P/E ratio is N/A. In terms of profitability, MED's ROE is -0.13%, compared to NEBCU's ROE of -0.00%. Regarding short-term risk, MED is less volatile compared to NEBCU. This indicates lower risk in terms of short-term price fluctuations for MED.Check NEBCU's competition here

Medifast, Inc. (NYSE: MED) plays a significant role within the Consumer Cyclical sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, MED stands at 131.1M. In comparison, STON has a market cap of 0. Regarding current trading prices, MED is priced at $11.77 on the NYSE, while STON trades at $3.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

MED currently has a P/E ratio of -9.59, whereas STON's P/E ratio is -6.64. In terms of profitability, MED's ROE is -0.13%, compared to STON's ROE of +0.48%. Regarding short-term risk, MED is more volatile compared to STON. This indicates higher risk in terms of short-term price fluctuations for MED.Check STON's competition here